Exhibit 8.1
GROUP SUBSIDIARIES*
At December 31, 2022 |
| Country |
| Percentage of voting |
Wholly owned subsidiaries |
|
| ||
Alexion Pharmaceuticals, Inc. | | United States | | 100 |
Alexion Pharma International Operations Limited | | Ireland | | 100 |
AstraZeneca AB | | Sweden | | 100 |
AstraZeneca Biotech AB | | Sweden | | 100 |
AstraZeneca Dunkerque Production SCS | | France | | 100 |
AstraZeneca Finance and Holdings Inc. | | United States | | 100 |
AstraZeneca Intermediate Holdings Limited | | England | | 100 |
AstraZeneca Pharmaceuticals Co., Limited | China | 100 | ||
AstraZeneca Pharmaceuticals LP | | United States | | 100 |
AstraZeneca Treasury Limited | England | 100 | ||
AstraZeneca UK Limited | England | 100 | ||
AstraZeneca (Wuxi) Trading Co. Ltd | China | 100 | ||
IPR Pharmaceuticals, Inc. | | Puerto Rico | | 100 |
MedImmune, LLC | | United States | | 100 |
* Subsidiary companies which would be deemed to be a “significant subsidiary” in accordance with rule 1-02(w) of Regulation S-X as at December 31, 2022.